Nkcfo LLC Acquires Shares of 5,000 Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Nkcfo LLC bought a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 5,000 shares of the company’s stock, valued at approximately $227,000.

Other large investors have also modified their holdings of the company. Mudita Advisors LLP raised its position in Establishment Labs by 49.7% in the fourth quarter. Mudita Advisors LLP now owns 142,400 shares of the company’s stock worth $3,687,000 after acquiring an additional 47,284 shares in the last quarter. Stableford Capital II LLC purchased a new position in shares of Establishment Labs in the 1st quarter valued at about $1,568,000. BNP Paribas Financial Markets lifted its stake in shares of Establishment Labs by 32,968.7% in the first quarter. BNP Paribas Financial Markets now owns 97,222 shares of the company’s stock valued at $4,949,000 after purchasing an additional 96,928 shares during the period. Swiss National Bank boosted its holdings in Establishment Labs by 13.6% during the first quarter. Swiss National Bank now owns 37,500 shares of the company’s stock worth $1,909,000 after buying an additional 4,500 shares in the last quarter. Finally, Concurrent Investment Advisors LLC acquired a new position in Establishment Labs during the first quarter worth about $263,000. 72.91% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Establishment Labs

In related news, CEO Quiros Juan Jose Chacon sold 6,839 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $45.30, for a total transaction of $309,806.70. Following the transaction, the chief executive officer now directly owns 218,896 shares in the company, valued at $9,915,988.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 14,346 shares of company stock worth $647,806 over the last quarter. 11.44% of the stock is currently owned by insiders.

Establishment Labs Trading Down 3.4 %

Shares of ESTA stock opened at $42.45 on Friday. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -13.52 and a beta of 1.20. The company has a current ratio of 4.44, a quick ratio of 2.91 and a debt-to-equity ratio of 4.30. The firm has a 50-day moving average price of $43.62 and a 200 day moving average price of $47.60. Establishment Labs Holdings Inc. has a twelve month low of $16.96 and a twelve month high of $60.12.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. The firm had revenue of $44.12 million during the quarter, compared to analyst estimates of $43.10 million. During the same period in the prior year, the firm earned ($0.65) EPS. The business’s quarterly revenue was down 9.2% on a year-over-year basis. Research analysts forecast that Establishment Labs Holdings Inc. will post -2.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ESTA has been the subject of a number of research reports. Citigroup lifted their price target on shares of Establishment Labs from $41.00 to $45.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. JPMorgan Chase & Co. decreased their target price on Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Mizuho raised their price target on Establishment Labs from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, June 6th. Finally, Stephens reiterated an “overweight” rating and issued a $68.00 price objective on shares of Establishment Labs in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $56.60.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.